Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000085896 | SCV000567323 | pathogenic | not provided | 2019-07-09 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect with loss of enzyme activity (Mondal et al., 2016); This variant is associated with the following publications: (PMID: 10987646, 23085273, 28976636, 28451379, 27537549, 31589614) |
Genome- |
RCV001588916 | SCV001821961 | likely pathogenic | Tyrosinase-negative oculocutaneous albinism | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000085896 | SCV002229123 | pathogenic | not provided | 2024-11-14 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with tyrosine, which is neutral and polar, at codon 371 of the TYR protein (p.Asn371Tyr). This variant is present in population databases (rs61754386, gnomAD 0.004%). This missense change has been observed in individual(s) with oculocutaneous albinism (PMID: 10987646, 28976636). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 99534). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt TYR protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects TYR function (PMID: 27537549). This variant disrupts the p.Asn371 amino acid residue in TYR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 1676041, 8434585). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005008001 | SCV005631375 | likely pathogenic | Tyrosinase-negative oculocutaneous albinism; Oculocutaneous albinism type 1B; SKIN/HAIR/EYE PIGMENTATION 3, LIGHT/DARK SKIN | 2023-12-29 | criteria provided, single submitter | clinical testing | |
Retina International | RCV000085896 | SCV000118039 | not provided | not provided | no assertion provided | not provided |